MetaCap

Ginkgo Bioworks (DNA) vs IRulya Therapeutics (IRLA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Ginkgo Bioworks is the larger company by market cap ($483.5 million vs $432.4 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

DNA+9.87%IRLA+17.16%
+128%+50%-29%
Aug 14, 20261 yearNov 20, 2026
DNA+9.87%IRLA+17.16%
+97%+39%-20%
Aug 10, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

DNA versus IRLA key metrics
MetricDNAIRLA
Share price$7.46$39.88
Market cap$483.54M$432.36M
1-day change-9.02%-0.15%
YTD return-10.23%—
1-year return-8.69%—
5-year return-98.45%—
EPS (TTM)$-4.24$-162.79
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$170.16M—
Revenue growth (YoY)-25.06%—
Net income (latest FY)$-312.76M$-83.98M
Operating margin-185.29%—
Net margin-183.81%—
52-week high$18.22$910.00
52-week low$5.37$15.10
Distance from 52-week high-59.06%-95.62%
Analyst consensusunderperformstrong_buy
Avg. price target upside+7.24%+90.90%
Average volume2.53M63.03K
Shares outstanding53.94M10.84M
Employees48538
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Ginkgo Bioworks

DNA stock →

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 485 employees

About IRulya Therapeutics

IRLA stock →

IRulya Therapeutics Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidate comprises eDSP, which is in Phase 3 for the treatment of rare pediatric neurodegenerative diseases, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in the ATM gene.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 38 employees

DNA vs IRLA FAQ

Which is bigger, Ginkgo Bioworks or IRulya Therapeutics?

Ginkgo Bioworks (DNA) is larger, with a market capitalization of $483.54M compared with $432.36M for IRulya Therapeutics (IRLA).

Are Ginkgo Bioworks and IRulya Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons